Medicines planning
47 results
Applied filters
The licence and supporting evidence for omalizumab biosimilar
20 April 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. Review its indications, evidence, and main differences.
Preparing to use omalizumab biosimilar
20 April 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. We offer general information and implementation advice.
Preparing to use denosumab 60mg biosimilar
16 January 2026Biosimilars of denosumab 60mg (Prolia) are available. We offer general information and implementation advice.
Preparing to use denosumab 120mg biosimilar
16 January 2026Biosimilars of denosumab 120mg (Xgeva) are available. We offer general information and implementation advice.
Understanding biological and biosimilar medicines
1 August 2025Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
Understanding data exclusivity and market protection
11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Understanding patents
11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
Understanding biosimilar and generic market entry
12 September 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.
Preparing to use aflibercept 2mg biosimilar
3 February 2026Aflibercept 2mg biosimilars for use in ophthalmology are available for NHS use. We offer general information and implementation advice.
Preparing to use golimumab biosimilar
9 January 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.